

Triple-drug combo could prove key weapon in fight against cancer

27 October 2021




Fig. 1: VBaP kills AML cell lines. a HL60, K562, KG1a and NB4 cells were treated with vehicle control (CON), 0.6 mM Valproic acid (VAL), 0.5 mM BEZ and 5 μ M MPA (BaP 0.5 mM), 0.1 mM BEZ and 5 μ M MPA (BaP 0.1 mM), the combination of Valproic acid 0.6 mM and BaP 0.1 mM (VBaP) for 7 days with feeding and retreating every 2 days and numbers of surviving cells determined by flow cytometry. Bar charts shows mean \pm SEM for n = 3–7 experiments. b HL60, K562, KG1a, and NB4 cells were treated as shown for 4 days and Annexin V binding determined using flow cytometry. FACS plots show representative Annexin V/PI staining for NB4 cells and bar graphs show mean \pm SEM for n = 4 experiments. Different letters indicate significant difference from other treatment groups as determined by ANOVA (p

APA citation: Triple-drug combo could prove key weapon in fight against cancer (2021, October 27) retrieved 23 January 2022 from <https://medicalxpress.com/news/2021-10-triple-drug-combo-key-weapon-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.